Home > Boards > US Listed > Biotechs > Inovio Pharmaceuticals, Inc. (INO)

Oppenheimer reiterated a "buy" rating and set a

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Lakers_w Member Profile
 
Followed By 13
Posts 3,024
Boards Moderated 1
Alias Born 04/26/07
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/18/2022 4:06:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2022 4:04:45 PM
Is 15% Potential Upside Good Enough to Risk Buying Inovio Stock? Analyst Weighs In TipRanks - 12/30/2021 3:49:03 PM
Inovio assumed with Hold at Jefferies with $6 target Seeking Alpha - 12/29/2021 9:55:07 AM
Inovio: Making Progress in the Cervical HSIL Program TipRanks - 12/15/2021 7:12:43 PM
INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18 PR Newswire (US) - 12/14/2021 8:00:00 AM
INOVIO starting development of Omicron-specific COVID vaccine candidate Seeking Alpha - 11/30/2021 9:03:04 AM
INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants PR Newswire (US) - 11/30/2021 8:00:00 AM
INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201 PR Newswire (US) - 11/16/2021 8:00:00 AM
INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference PR Newswire (US) - 11/15/2021 8:00:00 AM
Inovio Stock at $35 a Share? This Analyst Thinks It’s Possible TipRanks - 11/12/2021 6:22:17 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/9/2021 4:51:53 PM
Inovio targets H1 2022 to share interim data from late-stage trial for COVID-19 shot Seeking Alpha - 11/9/2021 4:37:51 PM
Inovio Pharmaceuticals EPS beats by $0.04, misses on revenue Seeking Alpha - 11/9/2021 4:11:04 PM
INOVIO Reports Third Quarter 2021 Financial Results PR Newswire (US) - 11/9/2021 4:05:00 PM
INOVIO wins FDA clearance to proceed with late-stage study for COVID-19 shot Seeking Alpha - 11/9/2021 8:35:04 AM
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S. PR Newswire (US) - 11/9/2021 8:00:00 AM
Inovio Pharmaceuticals Q3 2021 Earnings Preview Seeking Alpha - 11/8/2021 11:47:11 AM
INOVIO Expands Executive Leadership to Prepare for Commercial Operations PR Newswire (US) - 11/5/2021 8:00:00 AM
INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India PR Newswire (US) - 11/3/2021 8:00:00 AM
AstraZeneca unit terminates cancer vaccine program with Inovio Seeking Alpha - 10/29/2021 5:54:50 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/29/2021 5:02:40 PM
Inovio COVID-19 vaccine candidate to undergo WHO-sponsored trial Seeking Alpha - 10/28/2021 9:09:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/28/2021 6:11:14 AM
INOVIO to Report Third Quarter 2021 Financial Results on November 9, 2021 PR Newswire (US) - 10/27/2021 8:00:00 AM
Lakers_w   Friday, 09/10/21 03:06:39 PM
Re: None
Post # of 39805 
Oppenheimer reiterated a "buy" rating and set a $35.00 target price on shares of Inovio Pharmaceuticals in a research note on Friday, July 2nd. Jefferies Financial Group initiated coverage on Inovio Pharmaceuticals in a research note on Thursday, June 24th. They set a "hold" rating and a $9.00 price objective on the stock. Zacks Investment Research cut Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, August 13th.

Ino was downgraded by investment analysts at Bank of America from a "neutral" rating to an "underperform" rating in a research note issued to investors on Sept 10th. They presently have a $8.00 target price, down from their prior target price of $9.00.

Inovio downgraded to Underperform from Neutral at BofA BofA analyst Geoff Meacham downgraded Inovio to Underperform from Neutral with a price target of $8, down from $9. Meacham continues to see limited opportunity from the COVID-19 asset, for which he believes there is still meaningful value being reflected in the share price, the analyst tells investors in a research note.

Read more at:
https://thefly.com/n.php?id=3370280

Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company's stock. Inovio Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $14.13.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences